Dr. David Goldstein presents a significant intelligence gap for plaintiff attorneys, as his credentials, specialty, and institutional affiliation remain unverified despite his appearance in federal pharmaceutical litigation. Based on available PACER records, Goldstein has exclusively testified for plaintiffs in pharmaceutical cases, specifically appearing three times in Villarreal v. Taro Pharmaceuticals in the Southern District of Texas in 2017. The nature of this case suggests potential expertise in pharmaceutical manufacturing, drug safety, or regulatory compliance, but without confirmed credentials or institutional backing, his actual qualifications remain opaque. This lack of transparent professional background represents a critical weakness for any expert witness in complex mass tort litigation. Goldstein's courtroom track record is limited but exclusively plaintiff-sided, with no recorded Daubert challenges across his documented appearances. While this might initially appear favorable, the absence of Daubert testing combined with his concentration in a single case against Taro Pharmaceuticals suggests limited judicial scrutiny of his methodologies and opinions. For plaintiff attorneys, Goldstein represents a high-risk expert choice due to the credentialing uncertainty and narrow case exposure. Defense counsel would likely target his unverified background and apparent lack of peer recognition or institutional credibility. Without established credentials, published research, or a track record of surviving rigorous cross-examination, Goldstein's reliability as a witness in high-stakes pharmaceutical litigation remains questionable, making him vulnerable to effective Daubert challenges that could exclude his testimony entirely.
No Daubert challenges on record.
Free during beta. Your inquiry will be sent to MTAA and the expert if they've claimed their profile.
We'll send a verification link to your email. Once verified you can add contact info, bio, and availability.